Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The ...
Daratumumab and hyaluronidase-fihj are approved for high-risk smoldering multiple myeloma, offering a new subcutaneous treatment option. The AQUILA trial showed a 51% reduced mortality risk and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results